Quantitative Imaging Tools for Lung Cancer Drug Assessment

Presents chapters written by leading clinical researchers in the field of lung cancer, where high resolution 3–D imaging technology appears to hold the greatest near–term promise, as well as contributions from recognized experts in CAD, medical information technology systems, regulatory procedure, x–ray standards development, and clinical trial design. These expert contributors discuss the current state of the art and provide a road map for directing further research in lung cancer as well as other organ systems.

Spis treści:
Preface (Thomas M. Baer and James L. Mulshine).
Chapter 1: Incorporating Imaging into Drug Development: An Industry Perspective (Philip S. Murphy and Debasish Roychowdhury).
Chapter 2: Developing Imaging Tools for Drug Development: Critical Technology, Clinical Data and Regulatory (Rafal Dziadziuszko, Fred R. Hirsch and Paul A. Bunn, Jr).
Chapter 3: Quantitative Imaging in CT Lung Cancer Drug Development and Evaluation (Ricardo S. Avila).
Chapter 4: Volumetric CT Imaging for Response Assessment in Lung Cancer: A Platform for Translational Research (Binsheng Zhao and Lawrence H. Scwhartz).
Chapter 5: Emerging Radiological Software Standards and Development Technologies: Impact on Clinical Translation and Trials (John Pearson, Lawrence Tarbox, Gianluca Paladini, John G. Wolodzko, Paula M. Jacobs, and Zhenghong Lee).
Chapter 6: Statistical Considerations Underlying Therapeutic Response Criteria for Lung Cancer: A Review in the Context of Emergence of Multi–Slice CT Scanner and Computer Assisted Diagnostic Algorithm for Volumetric Assessment (Madhu Mazumdar and Xi Kathy Zhou).
Chapter 7: Programs Supporting Quantitative Imaging in Biomedicine at the National Institute for Standards and Technology (Thomas M. Baer and Charles W. Clark).
Appendix A: Evolving Imaging Resources: Public Access Databases (Laurence Clarke).
Appendix B: Biomedical Imaging Archive Network (Thomas M. Ba er and James L. Mulshine).
Appendix C: Developing CT Image–Processing Tools to Accelerate Progress in Lung Cancer Drug Development (James L. Mulshine, Ricardo S. Avila, Fred R. Hirsch, and David Yankelevitz).